Carolin Kurz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolin Kurz has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
Robert Perneczky
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
13 shared publicationsAnna Hufnagel
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
10 shared publications- Robert Perneczky
Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
9 shared publications - Boris-Stephan Rauchmann
Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
7 shared publications Paulina Tegethoff
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
7 shared publications- Paulina Tegethoff
Department of Psychiatry and Psychotherapy, LMU Hospital, LMU Munich, Munich, Germany
5 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Evaluating plasma phosphorylated tau217 for clinical rule-out of cerebral amyloid pathology: Evidence from a memory clinic cohort
Background: Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease amyloid-β (Aβ) pathology, but cut-offs require validation. Objective: The aim was to evaluate the diagnostic performance of plasma phosphorylated tau 217 for identifying cerebral amyloid pathology to reduce the need for more invasive or resource-intensive confirmatory testing by identifying individuals with a low likelihood of amyloid pathology. Methods: Elecsys ® pTau217 was evaluated in a memory clinic cohort using ROC analysis. Cut-offs were derived using sensitivity-weighted Euclidean distance and bootstrap resampling. Results: pTau217 discriminated Aβ-positive from Aβ-negative individuals (AUC 0.854). The cut-off was 0.169 pg/mL (95% CI 0.140–0.200), with 87.7% sensitivity and 77.0% specificity. Age and sex adjustment did not improve performance. Conclusions: The threshold was consistent with previously reported low cut-offs, supporting potential rule-out utility; however, its sensitivity precludes stand-alone exclusion of Aβ pathology in memory clinic populations.
- 1 November 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Open AccessEvaluating plasma phosphorylated tau217 for clinical rule-out of cerebral amyloid pathology: Evidence from a memory clinic cohort
Background: Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease amyloid-β (Aβ) pathology, but cut-offs require validation. Objective: The aim was to evaluate the diagnostic performance of plasma phosphorylated tau 217 for identifying cerebral amyloid pathology to reduce the need for more invasive or resource-intensive confirmatory testing by identifying individuals with a low likelihood of amyloid pathology. Methods: Elecsys ® pTau217 was evaluated in a memory clinic cohort using ROC analysis. Cut-offs were derived using sensitivity-weighted Euclidean distance and bootstrap resampling. Results: pTau217 discriminated Aβ-positive from Aβ-negative individuals (AUC 0.854). The cut-off was 0.169 pg/mL (95% CI 0.140–0.200), with 87.7% sensitivity and 77.0% specificity. Age and sex adjustment did not improve performance. Conclusions: The threshold was consistent with previously reported low cut-offs, supporting potential rule-out utility; however, its sensitivity precludes stand-alone exclusion of Aβ pathology in memory clinic populations.
- Open Access
- 24 October 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
A prospective observational study measuring the stability of plasma pTau181 using the Elecsys Phospho-Tau (181P) plasma immunoassay for early detection of Alzheimer’s disease
Background: Plasma tau phosphorylated at threonine 181 (pTau181) is a key blood-based biomarker that correlates with the burden of amyloid-beta (Aβ) pathology in Alzheimer’s disease (AD). The Elecsys ® Phospho-Tau (181P) Plasma (pT181p) immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) is intended for use as an aid in the early detection of Aβ pathology in adults ≥ 55 years presenting with complaints of cognitive decline and is Conformité Européenne-marked and approved for clinical use by the US FDA. Here, we evaluated the stability of plasma pTau181 measured using the pT181p immunoassay under different pre-analytical and storage conditions in samples from an intended-use population. Methods: Whole blood samples from individuals presenting at LMU Hospital with symptom severity ranging from subjective cognitive decline to moderate AD dementia were collected in three different tubes for plasma preparation (Li-Heparin, K2-EDTA, and K3-EDTA). These were transported under cooled (never frozen) conditions to the measurement site and processed within 6 h of collection. Plasma samples were stored at different temperatures for varying durations, and impact on plasma pTau181 recoveries was assessed. Results: Out-of-specification results not meeting pre-defined acceptance criteria observed in an initial cohort ( n = 14), were found to be the result of buffy coat/erythrocyte contamination. Pre-analytical procedures were modified to prevent contamination during post-centrifugation plasma transfer. In samples from a separate cohort ( n = 10), no instabilities were observed and acceptance criteria were met. After considering safety margins, analyte stability for all sample types was determined to be 2 days at 25 °C, 7 days at 4 °C, 12 weeks at -20 °C, and 16 weeks at -80°C; stability was also observed after one freeze/thaw cycle. Conclusions: pT181p immunoassay measurements were stable and robust with respect to different sample handling procedures and storage conditions. These findings support implementation of the assay into routine, non-specialist healthcare settings to facilitate practical blood-based testing to rule out AD-related Aβ pathology.
- 24 October 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessA prospective observational study measuring the stability of plasma pTau181 using the Elecsys Phospho-Tau (181P) plasma immunoassay for early detection of Alzheimer’s disease
Background: Plasma tau phosphorylated at threonine 181 (pTau181) is a key blood-based biomarker that correlates with the burden of amyloid-beta (Aβ) pathology in Alzheimer’s disease (AD). The Elecsys ® Phospho-Tau (181P) Plasma (pT181p) immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) is intended for use as an aid in the early detection of Aβ pathology in adults ≥ 55 years presenting with complaints of cognitive decline and is Conformité Européenne-marked and approved for clinical use by the US FDA. Here, we evaluated the stability of plasma pTau181 measured using the pT181p immunoassay under different pre-analytical and storage conditions in samples from an intended-use population. Methods: Whole blood samples from individuals presenting at LMU Hospital with symptom severity ranging from subjective cognitive decline to moderate AD dementia were collected in three different tubes for plasma preparation (Li-Heparin, K2-EDTA, and K3-EDTA). These were transported under cooled (never frozen) conditions to the measurement site and processed within 6 h of collection. Plasma samples were stored at different temperatures for varying durations, and impact on plasma pTau181 recoveries was assessed. Results: Out-of-specification results not meeting pre-defined acceptance criteria observed in an initial cohort ( n = 14), were found to be the result of buffy coat/erythrocyte contamination. Pre-analytical procedures were modified to prevent contamination during post-centrifugation plasma transfer. In samples from a separate cohort ( n = 10), no instabilities were observed and acceptance criteria were met. After considering safety margins, analyte stability for all sample types was determined to be 2 days at 25 °C, 7 days at 4 °C, 12 weeks at -20 °C, and 16 weeks at -80°C; stability was also observed after one freeze/thaw cycle. Conclusions: pT181p immunoassay measurements were stable and robust with respect to different sample handling procedures and storage conditions. These findings support implementation of the assay into routine, non-specialist healthcare settings to facilitate practical blood-based testing to rule out AD-related Aβ pathology.
- Open Access
- 3 September 2026
- Published by Elsevier in Aging Brain
- Vol. 10
Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease
- 3 September 2026
- Published by Elsevier in Aging Brain
- Vol. 10
Open AccessHealth-related factors and their impact on blood-based biomarkers of Alzheimer's disease
- Open Access
- 17 August 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (7) , 3835-3846
Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer’s disease from controls
Background: Paper-pencil assessments face limitations in accessibility, lengthy administration, and interrater reliability. Digital tools may overcome these by offering user-friendly, non-verbal, and scalable assessments. This study investigated the diagnostic accuracy of BraincheX, a novel digital test battery focused on accessibility and usability, by comparing its subtest performance to CERAD-Plus equivalents. Methods: Fifty-six participants with early AD and amyloid negative cognitively healthy controls were recruited from the LMU hospital memory clinic. Diagnostic groups were defined by amyloid positivity and clinical expert consensus according to the IWG-2 criteria. Participants completed the BraincheX digital battery and CERAD-Plus. BraincheX total score was calculated by summing standardized subtest scores. Data were analyzed using ROC analysis and the Youden Index. Correlations between subtests were examined, and group differences analyzed via ANOVA. Results: ROC analysis revealed strong diagnostic accuracy for the BraincheX total score in differentiating between early AD and controls (AUC = 0.86; optimal cut-off = − 1.51), with high sensitivity of 89.7% and moderate specificity of 68.0%. BraincheX total scores correlated with CERAD total scores ( r = .73, p < .001). BraincheX demonstrated good internal consistency (Cronbach’s α = 0.84). ANOVA confirmed significant group differences across all BraincheX subtests ( p < .01). Individual subtests showed strong correlations with CERAD-Plus equivalents. Conclusions: Findings suggest BraincheX as a promising, accessible digital screening tool for cognitive decline, offering automated scoring, immediate feedback, and reduced examiner bias. Future research is required to validate BraincheX in larger and more diverse populations and to establish BraincheX’s clinical applicability. Trial Registry: This analysis was conducted within the framework of the prospectively registered German SCD-Q validation study (NCT06711952). The registered study protocol included digital cognitive testing as part of the assessment protocol. The present manuscript reports a secondary analysis focusing on the diagnostic performance of BraincheX.
- 17 August 2026
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (7) , 3835-3846
Open AccessDiagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer’s disease from controls
Background: Paper-pencil assessments face limitations in accessibility, lengthy administration, and interrater reliability. Digital tools may overcome these by offering user-friendly, non-verbal, and scalable assessments. This study investigated the diagnostic accuracy of BraincheX, a novel digital test battery focused on accessibility and usability, by comparing its subtest performance to CERAD-Plus equivalents. Methods: Fifty-six participants with early AD and amyloid negative cognitively healthy controls were recruited from the LMU hospital memory clinic. Diagnostic groups were defined by amyloid positivity and clinical expert consensus according to the IWG-2 criteria. Participants completed the BraincheX digital battery and CERAD-Plus. BraincheX total score was calculated by summing standardized subtest scores. Data were analyzed using ROC analysis and the Youden Index. Correlations between subtests were examined, and group differences analyzed via ANOVA. Results: ROC analysis revealed strong diagnostic accuracy for the BraincheX total score in differentiating between early AD and controls (AUC = 0.86; optimal cut-off = − 1.51), with high sensitivity of 89.7% and moderate specificity of 68.0%. BraincheX total scores correlated with CERAD total scores ( r = .73, p < .001). BraincheX demonstrated good internal consistency (Cronbach’s α = 0.84). ANOVA confirmed significant group differences across all BraincheX subtests ( p < .01). Individual subtests showed strong correlations with CERAD-Plus equivalents. Conclusions: Findings suggest BraincheX as a promising, accessible digital screening tool for cognitive decline, offering automated scoring, immediate feedback, and reduced examiner bias. Future research is required to validate BraincheX in larger and more diverse populations and to establish BraincheX’s clinical applicability. Trial Registry: This analysis was conducted within the framework of the prospectively registered German SCD-Q validation study (NCT06711952). The registered study protocol included digital cognitive testing as part of the assessment protocol. The present manuscript reports a secondary analysis focusing on the diagnostic performance of BraincheX.
- Open Access
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Adaptive pathways for multimodal community-based detection of cognitive impairment: the CogScreen I study
Early detection of cognitive impairment is essential for dementia prevention and timely care. However, implementation in primary care and community settings remains limited. Building dementia-prepared health systems requires scalable and adaptive pathways that integrate subjective, digital and biological indicators, while accounting for heterogeneity in risk, education and age. CogScreen I was a cluster-randomized trial conducted in Munich senior centers from March 2023 to March 2024. Recruitment focused on community-dwelling adults aged ≥ 60 years reporting subjective cognitive concerns. Centers were randomized to: (A) the Subjective Cognitive Decline Questionnaire (SCD-Q) only, (B) SCD-Q plus digital cognitive testing, or (C) SCD-Q plus digital testing plus blood biomarkers (Aβ1-42/1–40, pTau181, GFAP, NfL). The primary endpoints were feasibility and acceptability, assessed through structured questionnaires and follow-up interviews with participants and general practitioners. Secondary endpoints examined latent cognitive structures and biomarker associations. Exploratory factor and clustering analyses revealed multimodal subgroups across subjective, digital, and biological measures, which informed a hypothesis-generating three-tier adaptive detection framework (low, medium, high intensity). Among the 473 participants (mean age 74.1 ± 7.6 years; 66% female; 63% with tertiary education), both feasibility and acceptability were high: Participants described the assessments as personally relevant, clearly communicated, and medically meaningful, and appreciated the added value of digital testing and biomarkers. Digital cognitive testing and biomarkers captured distinct latent dimensions of learning/working memory, psychomotor attention, and glial and amyloid pathology. Exploratory multimodal clustering identified three dementia risk profiles—low concern, intermediate, and at risk—which informed an adaptive, tiered detection model. Notably, subjective cognitive concerns assessed by the SCD-Q were strongly associated with overall subjective symptom burden, supporting the use of brief self-report questionnaires as a pragmatic and scalable first-step stratification approach in community-based dementia detection. Community-based, tiered detection pathways for cognitive decline are feasible, acceptable, and meaningful to older adults. Exploratory multimodal profiling suggests that combining subjective, digital, and biological measures may support individualized assessment strategies. However, limited GP engagement highlights the need for stronger integration with primary care to ensure downstream diagnostics and prevention pathways. The proposed framework remains hypothesis-generating and requires prospective validation. Clinical trials registered CogScreen has been registered at clinical trials (NCT06191952, 2023–12-20).
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAdaptive pathways for multimodal community-based detection of cognitive impairment: the CogScreen I study
Early detection of cognitive impairment is essential for dementia prevention and timely care. However, implementation in primary care and community settings remains limited. Building dementia-prepared health systems requires scalable and adaptive pathways that integrate subjective, digital and biological indicators, while accounting for heterogeneity in risk, education and age. CogScreen I was a cluster-randomized trial conducted in Munich senior centers from March 2023 to March 2024. Recruitment focused on community-dwelling adults aged ≥ 60 years reporting subjective cognitive concerns. Centers were randomized to: (A) the Subjective Cognitive Decline Questionnaire (SCD-Q) only, (B) SCD-Q plus digital cognitive testing, or (C) SCD-Q plus digital testing plus blood biomarkers (Aβ1-42/1–40, pTau181, GFAP, NfL). The primary endpoints were feasibility and acceptability, assessed through structured questionnaires and follow-up interviews with participants and general practitioners. Secondary endpoints examined latent cognitive structures and biomarker associations. Exploratory factor and clustering analyses revealed multimodal subgroups across subjective, digital, and biological measures, which informed a hypothesis-generating three-tier adaptive detection framework (low, medium, high intensity). Among the 473 participants (mean age 74.1 ± 7.6 years; 66% female; 63% with tertiary education), both feasibility and acceptability were high: Participants described the assessments as personally relevant, clearly communicated, and medically meaningful, and appreciated the added value of digital testing and biomarkers. Digital cognitive testing and biomarkers captured distinct latent dimensions of learning/working memory, psychomotor attention, and glial and amyloid pathology. Exploratory multimodal clustering identified three dementia risk profiles—low concern, intermediate, and at risk—which informed an adaptive, tiered detection model. Notably, subjective cognitive concerns assessed by the SCD-Q were strongly associated with overall subjective symptom burden, supporting the use of brief self-report questionnaires as a pragmatic and scalable first-step stratification approach in community-based dementia detection. Community-based, tiered detection pathways for cognitive decline are feasible, acceptable, and meaningful to older adults. Exploratory multimodal profiling suggests that combining subjective, digital, and biological measures may support individualized assessment strategies. However, limited GP engagement highlights the need for stronger integration with primary care to ensure downstream diagnostics and prevention pathways. The proposed framework remains hypothesis-generating and requires prospective validation. Clinical trials registered CogScreen has been registered at clinical trials (NCT06191952, 2023–12-20).
- Open Access
- 10 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112417
The DECISION Study: Protocol for the Development and Internal Validation of a Multimodal Decision-Making Capacity Framework
- 10 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112417
Open AccessThe DECISION Study: Protocol for the Development and Internal Validation of a Multimodal Decision-Making Capacity Framework
- Open Access
- 9 July 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (5) , 2377-2392
Defining and Measuring Cognitive Decline and Clinical Relevance
Current frameworks for cognitive impairment increasingly incorporate biomarker information, yet clinical classification remains grounded in the demonstration of objective cognitive decline and its functional consequences. This paper examines the balance between biological and clinical definitions and discusses implications for diagnosis, care, and research. Mild cognitive impairment (MCI) or mild neurocognitive disorder represents a clinically meaningful intermediate stage between normal aging and dementia, enabling early detection, timely intervention, and longitudinal monitoring. In routine care, comprehensive neuropsychological testing for all patients is not feasible; instead, a tiered diagnostic approach combining brief screening, clinical assessment, informant information, and targeted referral appears most practical and diagnostically robust. In research settings, outcomes that integrate cognitive performance with functional measures better capture clinically meaningful change than cognition-only endpoints. However, heterogeneity in definitions and outcome measures limits comparability across studies, and challenges remain regarding feasibility, cultural validity, and the integration of patient-relevant outcomes. Clinically useful definitions of cognitive impairment should integrate objective deficits with real-world impact. Pragmatic staged diagnostic pathways are best suited for routine care, while future work should focus on standardization, feasibility, and the alignment of research outcomes with patient-relevant benefits.
- 9 July 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (5) , 2377-2392
Open AccessDefining and Measuring Cognitive Decline and Clinical Relevance
Current frameworks for cognitive impairment increasingly incorporate biomarker information, yet clinical classification remains grounded in the demonstration of objective cognitive decline and its functional consequences. This paper examines the balance between biological and clinical definitions and discusses implications for diagnosis, care, and research. Mild cognitive impairment (MCI) or mild neurocognitive disorder represents a clinically meaningful intermediate stage between normal aging and dementia, enabling early detection, timely intervention, and longitudinal monitoring. In routine care, comprehensive neuropsychological testing for all patients is not feasible; instead, a tiered diagnostic approach combining brief screening, clinical assessment, informant information, and targeted referral appears most practical and diagnostically robust. In research settings, outcomes that integrate cognitive performance with functional measures better capture clinically meaningful change than cognition-only endpoints. However, heterogeneity in definitions and outcome measures limits comparability across studies, and challenges remain regarding feasibility, cultural validity, and the integration of patient-relevant outcomes. Clinically useful definitions of cognitive impairment should integrate objective deficits with real-world impact. Pragmatic staged diagnostic pathways are best suited for routine care, while future work should focus on standardization, feasibility, and the alignment of research outcomes with patient-relevant benefits.
- Open Access
- 25 June 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1) , 157
Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease
Background: Blood-based biomarkers are increasingly used to support the identification of Alzheimer’s disease (AD) in clinical and research settings. However, variability between analytical platforms limits their interchangeability and may affect their clinical interpretation. Direct head-to-head comparisons across assays and their alignment with clinical phenotypes remain limited. Objective: To compare the inter-test agreement of blood-based biomarkers measured using Roche and Fujirebio assays and to determine which biomarker shows the most robust analytical concordance and clinical relevance in AD. Methods: Participants with AD (n = 86) and cognitively healthy controls (HC; n = 56) underwent blood biomarker assessment using Roche and Fujirebio platforms. Plasma phosphorylated tau at threonine 217 (pTau217), plasma phosphorylated tau at threonine 181 (pTau181), Amyloid-β42 (Aβ42), amyloid-β40 (Aβ40), and the amyloid-β42/amyloid-β40 ratio (Aβ42/Aβ40) and glial fibrillary acidic protein (GFAP) were analyzed. Inter-test agreement was assessed using intraclass correlation coefficients, concordance analyses, and regression-based methods. Clinical relevance was evaluated by association with measures of cognitive and functional impairment evaluated using the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB). Analyses were adjusted for age and sex and complemented by sensitivity and stability analyses. Results: Inter-test agreement varied across biomarkers, with pTau217 demonstrating the highest and most stable concordance between Roche and Fujirebio assays. Among the evaluated markers, pTau217 also showed the strongest and most consistent associations with global cognition measures across diagnostic groups and best discriminated between individuals with AD and HC. GFAP demonstrated robust inter-test agreement but weaker alignment with clinical measures, while amyloid-based markers showed lower concordance and greater variability across platforms. Conclusions: Head-to-head comparison of Roche and Fujirebio assays revealed biomarker-specific differences in inter-test agreement, limiting the direct interchangeability of measurements across platforms. Plasma pTau217 showed the most consistent analytical concordance and clinical associations in this setting, supporting its potential utility in cross-platform applications. However, these findings also highlight the need for assay-specific calibration and cautious interpretation of biomarker thresholds in clinical and research use and the need for further validation across diverse populations. Trial registration: NCT05059158, NCT05317871
- 25 June 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1) , 157
Open AccessHead-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease
Background: Blood-based biomarkers are increasingly used to support the identification of Alzheimer’s disease (AD) in clinical and research settings. However, variability between analytical platforms limits their interchangeability and may affect their clinical interpretation. Direct head-to-head comparisons across assays and their alignment with clinical phenotypes remain limited. Objective: To compare the inter-test agreement of blood-based biomarkers measured using Roche and Fujirebio assays and to determine which biomarker shows the most robust analytical concordance and clinical relevance in AD. Methods: Participants with AD (n = 86) and cognitively healthy controls (HC; n = 56) underwent blood biomarker assessment using Roche and Fujirebio platforms. Plasma phosphorylated tau at threonine 217 (pTau217), plasma phosphorylated tau at threonine 181 (pTau181), Amyloid-β42 (Aβ42), amyloid-β40 (Aβ40), and the amyloid-β42/amyloid-β40 ratio (Aβ42/Aβ40) and glial fibrillary acidic protein (GFAP) were analyzed. Inter-test agreement was assessed using intraclass correlation coefficients, concordance analyses, and regression-based methods. Clinical relevance was evaluated by association with measures of cognitive and functional impairment evaluated using the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB). Analyses were adjusted for age and sex and complemented by sensitivity and stability analyses. Results: Inter-test agreement varied across biomarkers, with pTau217 demonstrating the highest and most stable concordance between Roche and Fujirebio assays. Among the evaluated markers, pTau217 also showed the strongest and most consistent associations with global cognition measures across diagnostic groups and best discriminated between individuals with AD and HC. GFAP demonstrated robust inter-test agreement but weaker alignment with clinical measures, while amyloid-based markers showed lower concordance and greater variability across platforms. Conclusions: Head-to-head comparison of Roche and Fujirebio assays revealed biomarker-specific differences in inter-test agreement, limiting the direct interchangeability of measurements across platforms. Plasma pTau217 showed the most consistent analytical concordance and clinical associations in this setting, supporting its potential utility in cross-platform applications. However, these findings also highlight the need for assay-specific calibration and cautious interpretation of biomarker thresholds in clinical and research use and the need for further validation across diverse populations. Trial registration: NCT05059158, NCT05317871
- Open Access
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
A multimodal framework for the assessment of decision-making capacity in neurocognitive disorders
BackgroundDecision-making capacity (DMC) is a prerequisite for valid informed consent, as well as being a key methodological requirement in clinical and epidemiological research. For individuals with neurocognitive disorders, DMC assessment is frequently based on subjective clinical judgement, with limited standardization and significant variability across settings. Current instruments are resource-intensive and not sufficiently adapted for stage-specific or real-world applications.ObjectiveTo develop a standardized, multimodal framework for assessing decision-making capacity, integrating neuropsychological, biological and contextual dimensions, and to define a validation strategy.MethodsWe propose a modular assessment framework that operationalizes the core domains of decision-making capacity: understanding, appreciation, reasoning and expression of choice. This is complemented by neuropsychological profiling, informant-based measures and structured decision scenarios. The framework is embedded in a prospective, multimodal cohort design spanning the neurocognitive disease spectrum. Validation is based on criterion-reference standards (MacCAT-T, CDR), psychometric analyses (factor analysis, reliability, ROC) and the integration of biological markers of neurodegeneration and disease stage. The co-design approach thus integrates both patient and caregiver perspectives as well as clinician and expert input, with focus group interviews providing a complementary, structured format to capture interdisciplinary professional perspectives.ResultsThe framework enables the structured, domain-specific and scalable assessment of decision-making capacity. It provides standardized scoring and quantifiable outputs, as well as a basis for stage-sensitive interpretation. It also allows the integration of biological context and real-world decision scenarios, thus facilitating both clinical applicability and research implementation.ConclusionsThis methodological framework provides a standardized, reproducible approach to assessing decision-making capacity in cognitively vulnerable populations. By integrating cognitive, biological and contextual dimensions, it enables more transparent, quantifiable and generalizable capacity assessment, with potential applications in clinical trials, observational studies and the design of ethically and legally compliant research.
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA multimodal framework for the assessment of decision-making capacity in neurocognitive disorders
BackgroundDecision-making capacity (DMC) is a prerequisite for valid informed consent, as well as being a key methodological requirement in clinical and epidemiological research. For individuals with neurocognitive disorders, DMC assessment is frequently based on subjective clinical judgement, with limited standardization and significant variability across settings. Current instruments are resource-intensive and not sufficiently adapted for stage-specific or real-world applications.ObjectiveTo develop a standardized, multimodal framework for assessing decision-making capacity, integrating neuropsychological, biological and contextual dimensions, and to define a validation strategy.MethodsWe propose a modular assessment framework that operationalizes the core domains of decision-making capacity: understanding, appreciation, reasoning and expression of choice. This is complemented by neuropsychological profiling, informant-based measures and structured decision scenarios. The framework is embedded in a prospective, multimodal cohort design spanning the neurocognitive disease spectrum. Validation is based on criterion-reference standards (MacCAT-T, CDR), psychometric analyses (factor analysis, reliability, ROC) and the integration of biological markers of neurodegeneration and disease stage. The co-design approach thus integrates both patient and caregiver perspectives as well as clinician and expert input, with focus group interviews providing a complementary, structured format to capture interdisciplinary professional perspectives.ResultsThe framework enables the structured, domain-specific and scalable assessment of decision-making capacity. It provides standardized scoring and quantifiable outputs, as well as a basis for stage-sensitive interpretation. It also allows the integration of biological context and real-world decision scenarios, thus facilitating both clinical applicability and research implementation.ConclusionsThis methodological framework provides a standardized, reproducible approach to assessing decision-making capacity in cognitively vulnerable populations. By integrating cognitive, biological and contextual dimensions, it enables more transparent, quantifiable and generalizable capacity assessment, with potential applications in clinical trials, observational studies and the design of ethically and legally compliant research.
- 1 April 2026
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 168 (6) , 48-54
Die neuen Alzheimer-Bluttests
- 1 April 2026
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 168 (6) , 48-54
Die neuen Alzheimer-Bluttests